GB201911403D0 - Conjugate and uses thereof - Google Patents
Conjugate and uses thereofInfo
- Publication number
- GB201911403D0 GB201911403D0 GBGB1911403.2A GB201911403A GB201911403D0 GB 201911403 D0 GB201911403 D0 GB 201911403D0 GB 201911403 A GB201911403 A GB 201911403A GB 201911403 D0 GB201911403 D0 GB 201911403D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1911403.2A GB201911403D0 (en) | 2019-08-09 | 2019-08-09 | Conjugate and uses thereof |
| US17/631,654 US20220275372A1 (en) | 2019-08-09 | 2020-08-07 | Conjugate and uses thereof |
| CN202510582562.XA CN120837670A (zh) | 2019-08-09 | 2020-08-07 | 缀合物及其用途 |
| CN202080071067.8A CN114615998B (zh) | 2019-08-09 | 2020-08-07 | 缀合物及其用途 |
| PCT/GB2020/051891 WO2021028666A1 (en) | 2019-08-09 | 2020-08-07 | Conjugate and uses thereof |
| BR112022002309A BR112022002309A2 (pt) | 2019-08-09 | 2020-08-07 | Conjugado e usos do mesmo |
| JP2022507761A JP7678654B2 (ja) | 2019-08-09 | 2020-08-07 | 複合体及びその使用 |
| KR1020227007655A KR20220079524A (ko) | 2019-08-09 | 2020-08-07 | 접합체 및 이의 용도 |
| MX2022001712A MX2022001712A (es) | 2019-08-09 | 2020-08-07 | Conjugados y usos de los mismos. |
| AU2020327659A AU2020327659A1 (en) | 2019-08-09 | 2020-08-07 | Conjugate and uses thereof |
| CA3149700A CA3149700A1 (en) | 2019-08-09 | 2020-08-07 | Conjugate and uses thereof |
| EP20754817.3A EP4010030A1 (en) | 2019-08-09 | 2020-08-07 | Conjugate and uses thereof |
| IL290424A IL290424A (en) | 2019-08-09 | 2022-02-07 | A bracelet and its uses |
| SA522431627A SA522431627B1 (ar) | 2019-08-09 | 2022-02-08 | متقارن واستخداماته |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1911403.2A GB201911403D0 (en) | 2019-08-09 | 2019-08-09 | Conjugate and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201911403D0 true GB201911403D0 (en) | 2019-09-25 |
Family
ID=67990936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1911403.2A Ceased GB201911403D0 (en) | 2019-08-09 | 2019-08-09 | Conjugate and uses thereof |
Country Status (13)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018150196A1 (en) | 2017-02-17 | 2018-08-23 | Oxford University Innovation Limited | Cell penetrating peptides modified by glycosylation |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| AU2019394177A1 (en) * | 2018-12-07 | 2021-06-10 | Oxford University Innovation Limited | Linkers |
| CA3211038A1 (en) | 2021-02-12 | 2022-08-18 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
| US20240189434A1 (en) * | 2021-03-12 | 2024-06-13 | Pepgen Inc. | Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates |
| IL321025A (en) * | 2022-11-21 | 2025-07-01 | Pepgen Inc | Cell-penetrating peptides, conjugates thereof, and methods of their use |
| EP4759826A1 (en) * | 2023-08-07 | 2026-06-17 | Toagosei Co., Ltd. | Peptide fragment and use thereof |
| WO2025033255A1 (ja) * | 2023-08-07 | 2025-02-13 | 東亞合成株式会社 | ペプチドフラグメント及びその利用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6047270B2 (ja) * | 2006-08-11 | 2016-12-21 | バイオマリン テクノロジーズ ベー.フェー. | Dnaリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段 |
| CA2691673A1 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2009147368A1 (en) * | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
| US20110269665A1 (en) * | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2013030569A2 (en) * | 2011-08-30 | 2013-03-07 | Michael John Gait | Peptides |
| US10111962B2 (en) | 2012-09-25 | 2018-10-30 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| RU2708237C2 (ru) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
-
2019
- 2019-08-09 GB GBGB1911403.2A patent/GB201911403D0/en not_active Ceased
-
2020
- 2020-08-07 KR KR1020227007655A patent/KR20220079524A/ko active Pending
- 2020-08-07 AU AU2020327659A patent/AU2020327659A1/en active Pending
- 2020-08-07 CN CN202080071067.8A patent/CN114615998B/zh active Active
- 2020-08-07 JP JP2022507761A patent/JP7678654B2/ja active Active
- 2020-08-07 BR BR112022002309A patent/BR112022002309A2/pt unknown
- 2020-08-07 CA CA3149700A patent/CA3149700A1/en active Pending
- 2020-08-07 CN CN202510582562.XA patent/CN120837670A/zh active Pending
- 2020-08-07 MX MX2022001712A patent/MX2022001712A/es unknown
- 2020-08-07 US US17/631,654 patent/US20220275372A1/en active Pending
- 2020-08-07 EP EP20754817.3A patent/EP4010030A1/en active Pending
- 2020-08-07 WO PCT/GB2020/051891 patent/WO2021028666A1/en not_active Ceased
-
2022
- 2022-02-07 IL IL290424A patent/IL290424A/en unknown
- 2022-02-08 SA SA522431627A patent/SA522431627B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022543320A (ja) | 2022-10-11 |
| CA3149700A1 (en) | 2021-02-18 |
| MX2022001712A (es) | 2022-05-13 |
| JP7678654B2 (ja) | 2025-05-16 |
| CN114615998A (zh) | 2022-06-10 |
| BR112022002309A2 (pt) | 2022-04-26 |
| CN120837670A (zh) | 2025-10-28 |
| US20220275372A1 (en) | 2022-09-01 |
| EP4010030A1 (en) | 2022-06-15 |
| KR20220079524A (ko) | 2022-06-13 |
| CN114615998B (zh) | 2025-05-23 |
| SA522431627B1 (ar) | 2024-05-19 |
| WO2021028666A1 (en) | 2021-02-18 |
| IL290424A (en) | 2022-04-01 |
| AU2020327659A1 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL294052B2 (en) | Fluoroalkyl oxadiazoles and their uses | |
| ZA202106612B (en) | Compounds and conjugates thereof | |
| IL290424A (en) | A bracelet and its uses | |
| IL285148A (en) | Diligand drug conjugate and its use | |
| SG11202101719PA (en) | Antibody-drug conjugate and application thereof | |
| ZA202003833B (en) | Conjugates and preparation and use thereof | |
| SG11202106612QA (en) | Improved antibody-oligonucleotide conjugate | |
| IL268102A (en) | Anti-GPR 20 antibody and anti-GPR 20 antibody-drug conjugate | |
| IL285177A (en) | compounds and their use | |
| SMT202400202T1 (it) | Coniugato anticorpo-farmaco anti-muc1-exatecano | |
| PT3626825T (pt) | Anticorpo anti-cdh6 e conjugado anticorpo anti-cdh6-fármaco | |
| IL278877B1 (en) | Amino-pyrazinecarboxamide compounds, conjugates and their uses | |
| IL286497A (en) | compounds and their use | |
| GB2591554B (en) | Composiitons and methods and uses relating thereto | |
| SG11202101517PA (en) | Isoquinoline-steroid conjugates and uses thereof | |
| IL291499A (en) | Azaquinoline compounds and their uses | |
| IL287503A (en) | Thio-semicarbazide compounds and their use | |
| ZA201905589B (en) | Drug-polymer conjugate | |
| PL4011898T3 (pl) | Pochodna 3-hydroksy-5-pregnan-20-onu i jej zastosowanie | |
| IL284764A (en) | compounds and their uses | |
| SG11202009242RA (en) | Short conjugated oligoelectrolytes and uses thereof | |
| ZA202005144B (en) | Parenteral formulations and uses thereof | |
| SG11202008543RA (en) | Pyrrolidineamide derivatives and uses thereof | |
| IL288828A (en) | Binding factors - cd38 and their use | |
| EP3266870A4 (en) | Conjugate and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |